Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.
Ursodeoxycholic acid treatment of patients with primary biliary cirrhosis may lead to relief of pruritus and improvement of biochemical liver tests. The changes in serum and urinary bile acids induced by ursodeoxycholic acid treatment were studied. After 29 patients with primary biliary cirrhosis were treated with ursodeoxycholic acid (750 to 1,000 mg/day) for 6 to 12 mo because of an increase in ursodeoxycholic acid, total plasma bile acids increased from 30.5 +/- 6 mumol/L (mean +/- S.E.M.) to 52.7 +/- 11.7 mumol/L (p less than 0.01). The increase in total plasma bile acids correlated significantly with concentrations of plasma bile acid before treatment (p less than 0.01). The concentrations of endogenous bile acids decreased, mainly because of a decrease of cholic acid. During treatment, glycine conjugation increased and taurine conjugation decreased, whereas sulfation and glucuronidation of bile acids were unchanged. In 10 patients with primary biliary cirrhosis in stages III and IV, urinary excretion of bile acids was also studied. After treatment, ursodeoxycholic acid and its 3-beta isomer and C-1-hydroxylated and C-6-hydroxylated derivatives were also excreted. During treatment, urinary excretion of endogenous bile acids decreased. The increase of ursodeoxycholic acid and the decrease of endogenous bile acids may both be related to the improvement of biochemical liver tests in precirrhotic stages of the disease. In cirrhosis, endogenous bile acids in plasma remained high and changes in liver tests were small.
Department of Internal Medicine, University of Heidelberg, FRG.
A
A
Stiehl
G
G
Rudolph
R
R
Raedsch
B
B
Möller
U
U
Hopf
E
E
Lotterer
J
J
Bircher
U
U
Fölsch
J
J
Klaus
R
R
Endele
D001647:Bile Acids and Salts / Q000032:analysis / Q000378:metabolism*; D002849:Chromatography, Gas; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism; D014580:Ursodeoxycholic Acid / Q000032:analysis / Q000493:pharmacokinetics / Q000627:therapeutic use*
D001647:Bile Acids and Salts; D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid